Murtola, Teemu J.
Vihervuori, Ville JY
Lahtela, Jorma
Talala, Kirsi
Taari, Kimmo
Tammela, Teuvo LJ
Auvinen, Anssi
Article History
Received: 4 September 2017
Revised: 20 February 2018
Accepted: 21 February 2018
First Online: 22 March 2018
Competing interests
: T.J.M.: lecture fees from Astellas, Janssen, and MSD, paid consultant for Astellas and Jansen. V.J.Y.V.: none. J.L.: none. K.T.: none, K.T.: lecture fee from GSK, consultant fee from Abbvie, research funding from Medivation, and congress travel support from Astellas and Orion. T.L.J.T.: paid consultant for Astellas, GSK, Pfizer, Orion Pharma, and Amgen, ad A.A.: lecture fee from MSD and paid consultant for Epid Research.
: The study has been approved by the ethics committee of the Pirkanmaa Hospital District, decision number R10167. The study was performed in accordance with the declaration of Helsinki.
: Data used in this study are available at request from the authors.